Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

81 results about "Histamine H3 receptor" patented technology

Histamine H₃ receptors are expressed in the central nervous system and to a lesser extent the peripheral nervous system, where they act as autoreceptors in presynaptic histaminergic neurons, and also control histamine turnover by feedback inhibition of histamine synthesis and release. The H₃ receptor has also been shown to presynaptically inhibit the release of a number of other neurotransmitters (i.e. it acts as an inhibitory heteroreceptor) including, but probably not limited to dopamine, GABA, acetylcholine, noradrenaline, histamine and serotonin.

2-Aminopyrimidine modulators of the histamine H4 receptor

2-Aminopyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.
Owner:JANSSEN PHARMA NV

Histamine h3 receptor agents, preparation and therapeutic uses

InactiveUS20100048580A1Selective and high affinity bindingBiocideOrganic chemistryDiseaseMedicine
The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases
Owner:ELI LILLY & CO

Substituted imidazoles, their preparation and use

Disclosed is a novel class of substituted imidazole compounds, pharmaceutical compositions containing them and uses of these compounds in the treatment and / or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, these compounds are useful for the treatment and / or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial. These imidazoles compounds have the formula I wherein R1, R2, R3, R4, R5, R6, A, X, Y and Z are as defined in the specification.
Owner:VTV THERAPEUTICS LLC

Pyrazole derivative

InactiveUS20100113776A1Excellent histamine H receptor antagonistic effectNervous disorderOrganic chemistryAttention deficitsCircadian Rhythm Disorders
A novel pyrazole derivative of the following formula having a histamine H3 receptor antagonistic effect:or a pharmaceutically acceptable salt thereof or a pharmaceutical preparation comprising the same as an active ingredient is effective for prevention or treatment of dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases.
Owner:TAISHO PHARMACEUTICAL CO LTD

Pyridine compounds as histamine H3 modulators

ActiveUS7423147B2BiocideNervous disorderHistamine H1 receptorHistamine H2 receptor
Certain non-imidazole heterocyclic compounds are Histamine H3 modulators in the treatment of Histamine H3 receptor mediated diseases.
Owner:JANSSEN PHARMA NV

Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor

Benzofuro- and benzothienopyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.
Owner:JANSSEN PHARMA NV

Novel Medicaments

Novel compounds which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system. The novel compounds have a core consisting of a 6 membered aromatic ring containing at least one nitrogen atom and two carbon atoms in the ring and, at the remaining positions in the ring, there is either a carbon or a nitrogen atom.
Owner:VTV THERAPEUTICS LLC

Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor

ActiveUS8084466B2BiocideOrganic chemistryHistamine H1 receptorDisease
Bicyclic heteroaryl-substituted imidazole compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.
Owner:JANSSEN PHARMA NV

Furan compounds as histamine H3 modulators

ActiveUS7429659B2Organic active ingredientsNervous disorderFuranHistamine H1 receptor
Certain furan compounds are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases.
Owner:JANSSEN PHARMA NV

Histamine H3 receptor antagonists

Novel compounds which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system. The novel compounds have a core consisting of a 6 membered aromatic ring containing at least one nitrogen atom and two carbon atoms in the ring and, at the remaining positions in the ring, there is either a carbon or a nitrogen atom.
Owner:HIGH POINT PHARMA

Novel Aryl- and Heteroarylpiperazines

Novel aryl- and heteroarylpiperazines, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases and disorders related to the histamine H3 receptor.
Owner:HIGH POINT PHARMA

Non-imidazole heterocyclic compounds

Certain non-imidazole heterocyclic compounds are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases.
Owner:JANSSEN PHARMA NV

Histamine h3 receptor agents, preparation and therapeutic uses

InactiveUS20070208024A1Selective and high affinity bindingHigh affinityBiocideNervous disorderHistamine Receptor AntagonistsTreatment use
The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases
Owner:ELI LILLY & CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products